|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | |||||||||||||||||
| ASSETS | |||||||||||||||||
| Cash | |||||||||||||||||
| Prepaid expenses | |||||||||||||||||
| Due from related party | |||||||||||||||||
| Other current assets | |||||||||||||||||
| Extension contribution due from Sponsor | |||||||||||||||||
| Class A Ordinary Shares Subject to Possible Redemption | |||||||||||||||||
| Total extension contribution due from Sponsor | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Cash held in Trust Account | |||||||||||||||||
| Total Assets | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Convertible promissory note - extension loan | |||||||||||||||||
| Promissory note - extension loan | |||||||||||||||||
| Extension Loan | |||||||||||||||||
| Total promissory note - extension loan | |||||||||||||||||
| Convertible promissory note - working capital loan | |||||||||||||||||
| Promissory note - working capital loan | |||||||||||||||||
| Due to related party | |||||||||||||||||
| Related Party | |||||||||||||||||
| Total due to related party | |||||||||||||||||
| Conversion option liability - extension and working capital loans | |||||||||||||||||
| Accrued expenses | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Deferred underwriting fees payable | |||||||||||||||||
| Derivative warrant liabilities | |||||||||||||||||
| Deferred underwriting fees payable | |||||||||||||||||
| Deferred underwriting fees payable | |||||||||||||||||
| Derivative warrant liabilities | |||||||||||||||||
| Deferred legal fees | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 1,513,954 and 6,290,711 shares at $12.11 and $11.77 per share at June 30, 2025 and December 31, 2024, respectively | |||||||||||||||||
| Class A Ordinary Shares Subject to Possible Redemption | |||||||||||||||||
| Total class A ordinary shares subject to possible redemption, $0.0001 par value; 1,513,954 and 6,290,711 shares at $12.11 and $11.77 per share at June 30, 2025 and December 31, 2024, respectively | |||||||||||||||||
| Shareholders' deficit | |||||||||||||||||
| Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 5,031,250 issued and outstanding at June 30, 2025 and December 31, 2024 respectively (excluding 6,290,711 shares subject to possible redemption) | |||||||||||||||||
| Class A Ordinary Shares | |||||||||||||||||
| Class B Ordinary Shares | |||||||||||||||||
| Total class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 5,031,250 issued and outstanding at June 30, 2025 and December 31, 2024 respectively (excluding 6,290,711 shares subject to possible redemption) | |||||||||||||||||
| Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 0 and 5,031,250 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total shareholders' deficit | |||||||||||||||||
| Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders' Deficit | |||||||||||||||||
Loading...
